Compare Diamondback Energy Inc (FANG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Diamondback Energy Inc trades at $200 (market cap $56.48B), while Vertex Pharmaceuticals Incorporated trades at $527.68 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.4× Diamondback Energy Inc's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| FANG | VRTX | |
|---|---|---|
Market Cap | $56.48B | $134.25B |
Sector | Energy | Health |
52-Week High | $213.69 | $529.65 |
52-Week Low | $134.53 | $376.62 |
Enterprise Value | $68.63B | $128.37B |
Dividend Yield | 2.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $198.97, up 5.81% with strong Q2 2026 earnings beating estimates. Technical indicators show bullish momentum with support at $193 and resistance at $202. Revenue grew to $14.93B in 2025, though profit margins compressed to 11.14%. Analyst consensus is strongly bullish with a $236.63 price target and 90% buy ratings.
FANG offers growth potential through production increases and debt reduction, supported by elevated oil prices. Risks include commodity price volatility and margin pressure from rising costs. The stock trades at a premium P/E of 38.42 but remains attractive given operational efficiency gains and institutional accumulation.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
